Evidence map›Paper›PMID 34612702›Full record

ArticleMicrobiology spectrum2021

Genome-Wide Association Study Reveals Genetic Markers for Antimicrobial Resistance in Mycoplasma bovis.

Jade Bokma, Nick Vereecke, Hans Nauwynck, Freddy Haesebrouck, Sebastiaan Theuns, Bart Pardon, Filip Boyen

Open access · goldAbstract read
In one paragraph

Article in Microbiology spectrum, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
6.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 57 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. The Pathogenomics of the RespiratoryPathogens (Basel, Switzerland) · 2025
    Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. The Genetic Landscape of Antimicrobial Resistance Genes inAntibiotics (Basel, Switzerland) · 2024
    Article
  15. Article
  16. Article
  17. Unravelling the mechanisms causing murepavadin resistance inFrontiers in cellular and infection microbiology · 2024
    Article
  18. Review
  19. Article
  20. Real-time genomics for One Health.Molecular systems biology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Jade Bokma *Department of Large Animal Internal Medicine, Faculty of Veterinary Medicine, Ghent Universitygrid.5342.0, Merelbeke, Belgium.ORCID 0000-0002-8854-1041
Nick Vereecke *Department of Virology, Parasitology, and Immunology, Faculty of Veterinary Medicine, Ghent Universitygrid.5342.0, Merelbeke, Belgium.ORCID 0000-0001-5367-9756
Hans NauwynckDepartment of Virology, Parasitology, and Immunology, Faculty of Veterinary Medicine, Ghent Universitygrid.5342.0, Merelbeke, Belgium.
Freddy HaesebrouckDepartment of Pathology, Bacteriology, and Avian Diseases, Faculty of Veterinary Medicine, Ghent Universitygrid.5342.0, Merelbeke, Belgium.
Sebastiaan TheunsDepartment of Virology, Parasitology, and Immunology, Faculty of Veterinary Medicine, Ghent Universitygrid.5342.0, Merelbeke, Belgium.
Bart PardonDepartment of Large Animal Internal Medicine, Faculty of Veterinary Medicine, Ghent Universitygrid.5342.0, Merelbeke, Belgium.
Filip BoyenDepartment of Pathology, Bacteriology, and Avian Diseases, Faculty of Veterinary Medicine, Ghent Universitygrid.5342.0, Merelbeke, Belgium.
Ghent University · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mycoplasma bovis causes many health and welfare problems in cattle. Due to the absence of clear insights regarding transmission dynamics and the lack of a registered vaccine in Europe, control of an outbreak depends mainly on antimicrobial therapy. Unfortunately, antimicrobial susceptibility testing (AST) is usually not performed, because it is time-consuming and no standard protocol or clinical breakpoints are available. Fast identification of genetic markers associated with acquired resistance may at least partly resolve former issues. Therefore, the aims of this study were to implement a first genome-wide association study (GWAS) approach to identify genetic markers linked to antimicrobial resistance (AMR) in M. bovis using rapid long-read sequencing and to evaluate different epidemiological cutoff (ECOFF) thresholds. High-quality genomes of 100 M. bovis isolates were generated by Nanopore sequencing, and isolates were categorized as wild-type or non-wild-type isolates based on MIC testing results. Subsequently, a k-mer-based GWAS analysis was performed to link genotypes with phenotypes based on different ECOFF thresholds. This resulted in potential genetic markers for macrolides (gamithromycin and tylosin) (23S rRNA gene and 50S ribosomal unit) and enrofloxacin (GyrA and ParC). Also, for tilmicosin and the tetracyclines, previously described mutations in both 23S rRNA alleles and in one or both 16S rRNA alleles were observed. In addition, two new 16S rRNA mutations were possibly associated with gentamicin resistance. In conclusion, this study shows the potential of quick high-quality Nanopore sequencing and GWAS analysis in the evaluation of phenotypic ECOFF thresholds and the rapid identification of M. bovis strains with acquired resistance.

Indexed as

AnimalsAnti-Bacterial AgentsCattleCattle DiseasesDrug Resistance, BacterialEnrofloxacinGenetic MarkersGenome, BacterialGenome-Wide Association StudyGentamicinsMacrolidesMicrobial Sensitivity TestsMycoplasma bovisTetracyclinesTylosinAnti-Bacterial AgentsEnrofloxacinGenetic MarkersGentamicinsMacrolidesTetracyclinestilmicosinTylosinepidemiological cutofffluoroquinolonesgamithromycingentamicinmacrolidesNanopore sequencing

Identifiers

PMID34612702
PMCPMC8510175
OpenAlexW3203636020

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.